AAP
SNDX icon

Arax Advisory Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Arax Advisory Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Buy
6,812
+6,227
+1,064% +$129K ﹤0.01% 2448
2026
Q1 		$13.6K Buy
585
+268
+85% +$5.82K ﹤0.01% 2287
2025
Q4 		$6.66K Sell
317
-4,580
-94% -$79.9K ﹤0.01% 2697
2025
Q3 		$75.3K Buy
4,897
+4,690
+2,266% +$61.4K ﹤0.01% 1650
2025
Q2 		$1.94K Buy
+207
New +$2.28K ﹤0.01% 2575
2024
Q4 		– Sell
-14
Closed -$270 – 2725
2024
Q3 		$270 Buy
+14
New +$289 ﹤0.01% 2483

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Arax Advisory Partners's SNDX Position: Q2 2026 in Review

Arax Advisory Partners increased its Syndax Pharmaceuticals (SNDX) stake by 1,064% in Q2 2026, buying an estimated $129K and bringing the position to 6,812 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Arax Advisory Partners first reported a position in SNDX in Q3 2024 and has held it in 6 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Arax Advisory Partners held 6,812 shares of Syndax Pharmaceuticals worth $149K as of Q2 2026.
  • Arax Advisory Partners bought 6,227 Syndax Pharmaceuticals shares in Q2 2026, an estimated $129K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2448 holding.
  • Arax Advisory Partners first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.